查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1604580

抗精神病藥物市場：按類別、適應症 - 2025-2030 年全球預測

Antipsychotic Drugs Market by Class (First Generation, Second Generation, Third Generation), Indication (Bipolar Disorders, Dementia, Schizophrenia) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年抗精神病藥物市場價值為96.5億美元，預計到2024年將達到104.2億美元，複合年成長率為8.01%，到2030年將達到165.6億美元。

抗精神病藥物市場主要包括用於治療思覺失調症和雙相情感障礙等精神病相關疾病的藥物。這個市場的範圍延伸到各種心理健康應用，包括嚴重憂鬱症和焦慮症的治療。精神疾病發病率的上升以及全球意識和診斷率的提高支持了對這些藥物的需求。主要的最終用途領域包括醫院、診所和復健中心，它們利用這些藥物來穩定患者的心理狀態並提高他們的生活品質。該市場的關鍵成長要素包括精神健康疾病盛行率的增加、藥物配方的進步以及心理健康支持措施。開發副作用較少、療效較強的下一代抗精神病藥物的機會比比皆是。投資精神疾病的遺傳和生物學基礎的研究可以帶來個人化的藥物治療策略，並為公司的創新提供利潤豐厚的機會。數位療法與藥物治療相結合也代表了一個潛在的成長領域，特別是當科技融入醫療保健服務時。然而，影響市場開拓的限制因素包括藥物開發成本高、監管要求嚴格以及與精神疾病相關的恥辱感，這些可能會阻礙市場擴張。與現有抗精神病藥物相關的副作用（例如體重增加和代謝問題）等挑戰可能會阻止患者堅持制定的治療方案。為了克服這些限制，製藥公司可能會專注於透過新型藥物傳輸系統（例如緩釋性和經皮貼片）來減少副作用。總的來說，個人化醫療的創新、利用人工智慧進行藥物發現以及綜合心理健康服務的整合有潛力推動業務的顯著成長並改變治療格局，抗精神病藥物突顯了這一持續、複雜但充滿希望的性質的藥品市場。

主要市場統計
基準年[2023] 96.5億美元
預測年份 [2024] 104.2億美元
預測年份 [2030] 165.6億美元
複合年成長率（%） 8.01%

市場動態：揭示快速發展的抗精神病藥物市場的關鍵市場洞察

供需的動態交互作用正在改變抗精神病藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 精神疾病和相關疾病的盛行率增加
    • 政府藥品核准增加
    • 人們對心理健康和保健的認知不斷增強
  • 市場限制因素
    • 現有品牌專利到期
  • 市場機會
    • 新型抗精神病藥物的研發及臨床試驗
    • 改良抗精神病藥物測試
  • 市場問題
    • 嚴格的法律規範和合規性

波特的五力：駕馭抗精神病藥物市場的策略工具

波特五力：「框架是了解市場格局競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解抗精神病藥物市場的外部影響

外部宏觀環境因素在塑造抗精神病藥物市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解抗精神病藥物市場的競爭格局

抗精神病藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：抗精神病藥物市場供應商的績效評估

FPNV定位矩陣是評估抗精神病藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製抗精神病藥物市場的成功之路

抗精神病藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 精神疾病和相關疾病的盛行率增加
      • 政府藥品核准增加
      • 人們對心理健康和保健的認知不斷增強
    • 抑制因素
      • 現有品牌專利到期
    • 機會
      • 新型抗精神病藥物的研發及臨床試驗
      • 改良抗精神病藥物測試
    • 任務
      • 嚴格的法規結構和合規性
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章抗精神病藥物市場：依類別

  • 介紹
  • 第一代
    • 哈爾德
    • 納瓦內
  • 第二代
    • 象齒象
    • 因維加
    • 拉圖達
    • Risperdal
    • Seroquel
    • Zyprexa
  • 第三代
    • Abilify

第7章抗精神病藥物市場：依適應症分類

  • 介紹
  • 躁鬱症
  • 失智
  • 思覺失調症
  • 單相憂鬱症

第8章美洲抗精神病藥物市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太抗精神病藥物市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲的抗精神病藥物市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Alkermes, Inc.
  • AMBOSS GmbH
  • Amgen Inc
  • Arlak BIoTech
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories, Ltd.
  • Eli Lilly and Company
  • Flagship BIoTech International Pvt. Ltd.
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Johnson & Johnson Services Inc.
  • Lifecare Neuro Products Ltd.
  • Luye Pharma Group
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co. Ltd.
  • Pfizer, Inc.
  • S. Karger AG
  • Seqirus Pty Ltd
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Teva Pharmaceutical Industries, Ltd.
  • Vanda Pharmaceuticals Inc.
Product Code: MRR-AD36CD897CDF

The Antipsychotic Drugs Market was valued at USD 9.65 billion in 2023, expected to reach USD 10.42 billion in 2024, and is projected to grow at a CAGR of 8.01%, to USD 16.56 billion by 2030.

The antipsychotic drugs market encompasses medications primarily used to manage psychosis-related conditions such as schizophrenia and bipolar disorder. This market's scope extends to diverse mental health applications, including the treatment of severe depression and anxiety disorders. The necessity for these drugs is underscored by the rising incidence of mental health disorders and the expansion of awareness and diagnosis rates worldwide. The primary end-use sectors include hospitals, clinics, and rehabilitation centers, which utilize these medications to stabilize patients' psychological states and enhance their quality of life. Key growth factors for this market include the increasing prevalence of mental health conditions, advancements in drug formulations, and supportive mental health policies. Opportunities abound in developing next-generation antipsychotic drugs with fewer side effects and enhanced efficacy profiles. Investments in research focused on the genetic and biological underpinnings of psychiatric disorders could lead to personalized medication strategies, presenting a lucrative opportunity for businesses to innovate. Digital therapeutics, combined with pharmacological treatments, also represent a potential area for growth, especially as technology integrates into healthcare delivery. However, limitations affecting market growth include the high cost of drug development, stringent regulatory requirements, and the stigma associated with mental health disorders, which may hinder market expansion. Challenges such as side effects associated with existing antipsychotic drugs, including weight gain and metabolic issues, can deter patients from adherence to prescribed treatment regimes. To overcome these limitations, pharmaceutical companies might focus on reducing adverse effects through novel drug delivery systems, such as sustained-release formulations or transdermal patches. Overall, innovation in personalized medicine, leveraging artificial intelligence for drug discovery, and integrating comprehensive mental health services could drive significant business growth and transform the treatment landscape, highlighting the ongoing complex yet promising nature of the antipsychotic drugs market.

KEY MARKET STATISTICS
Base Year [2023] USD 9.65 billion
Estimated Year [2024] USD 10.42 billion
Forecast Year [2030] USD 16.56 billion
CAGR (%) 8.01%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antipsychotic Drugs Market

The Antipsychotic Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of psychosis and associated diseases
    • Rising drug approval from governments
    • Growing awareness regarding mental health and wellness
  • Market Restraints
    • Patent expiry of established brands
  • Market Opportunities
    • R&D and clinical trials for new antipsychotic drugs
    • Improvements in antipsychotic drug testing
  • Market Challenges
    • Stringent regulatory framework and compliance

Porter's Five Forces: A Strategic Tool for Navigating the Antipsychotic Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antipsychotic Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antipsychotic Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antipsychotic Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antipsychotic Drugs Market

A detailed market share analysis in the Antipsychotic Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antipsychotic Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antipsychotic Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antipsychotic Drugs Market

A strategic analysis of the Antipsychotic Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antipsychotic Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alkermes, Inc., AMBOSS GmbH, Amgen Inc, Arlak Biotech, AstraZeneca PLC, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories, Ltd., Eli Lilly and Company, Flagship Biotech International Pvt. Ltd., GlaxoSmithKline PLC, H. Lundbeck A/S, Johnson & Johnson Services Inc., Lifecare Neuro Products Ltd., Luye Pharma Group, Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co. Ltd., Pfizer, Inc., S. Karger AG, Seqirus Pty Ltd, Sumitomo Dainippon Pharma Co., Ltd., Teva Pharmaceutical Industries, Ltd., and Vanda Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Antipsychotic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Class, market is studied across First Generation, Second Generation, and Third Generation. The First Generation is further studied across Haldo and Navane. The Second Generation is further studied across Geodon, Invega, Latuda, Risperdal, Seroquel, and Zyprexa. The Third Generation is further studied across Abilify.
  • Based on Indication, market is studied across Bipolar Disorders, Dementia, Schizophrenia, and Unipolar Depression.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of psychosis and associated diseases
      • 5.1.1.2. Rising drug approval from governments
      • 5.1.1.3. Growing awareness regarding mental health and wellness
    • 5.1.2. Restraints
      • 5.1.2.1. Patent expiry of established brands
    • 5.1.3. Opportunities
      • 5.1.3.1. R&D and clinical trials for new antipsychotic drugs
      • 5.1.3.2. Improvements in antipsychotic drug testing
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory framework and compliance
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antipsychotic Drugs Market, by Class

  • 6.1. Introduction
  • 6.2. First Generation
    • 6.2.1. Haldo
    • 6.2.2. Navane
  • 6.3. Second Generation
    • 6.3.1. Geodon
    • 6.3.2. Invega
    • 6.3.3. Latuda
    • 6.3.4. Risperdal
    • 6.3.5. Seroquel
    • 6.3.6. Zyprexa
  • 6.4. Third Generation
    • 6.4.1. Abilify

7. Antipsychotic Drugs Market, by Indication

  • 7.1. Introduction
  • 7.2. Bipolar Disorders
  • 7.3. Dementia
  • 7.4. Schizophrenia
  • 7.5. Unipolar Depression

8. Americas Antipsychotic Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Antipsychotic Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Antipsychotic Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alkermes, Inc.
  • 3. AMBOSS GmbH
  • 4. Amgen Inc
  • 5. Arlak Biotech
  • 6. AstraZeneca PLC
  • 7. Bristol-Myers Squibb Company
  • 8. Daiichi Sankyo Company, Limited
  • 9. Dr. Reddy's Laboratories, Ltd.
  • 10. Eli Lilly and Company
  • 11. Flagship Biotech International Pvt. Ltd.
  • 12. GlaxoSmithKline PLC
  • 13. H. Lundbeck A/S
  • 14. Johnson & Johnson Services Inc.
  • 15. Lifecare Neuro Products Ltd.
  • 16. Luye Pharma Group
  • 17. Merck & Co., Inc.
  • 18. Novartis AG
  • 19. Otsuka Pharmaceutical Co. Ltd.
  • 20. Pfizer, Inc.
  • 21. S. Karger AG
  • 22. Seqirus Pty Ltd
  • 23. Sumitomo Dainippon Pharma Co., Ltd.
  • 24. Teva Pharmaceutical Industries, Ltd.
  • 25. Vanda Pharmaceuticals Inc.

LIST OF FIGURES

  • FIGURE 1. ANTIPSYCHOTIC DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIPSYCHOTIC DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ANTIPSYCHOTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ANTIPSYCHOTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIPSYCHOTIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIPSYCHOTIC DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HALDO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY NAVANE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GEODON, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INVEGA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY LATUDA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RISPERDAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SEROQUEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ZYPREXA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ABILIFY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY BIPOLAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY UNIPOLAR DEPRESSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 237. ANTIPSYCHOTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 238. ANTIPSYCHOTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023